Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: YORE who wrote (4929)	8/13/1998 10:35:00 PM
From: Bull-like	Read Replies (1) \| Respond to of 9523

yore, Historically, pfe always looks to grow internally. Growth through acquisition is generally not their strategy. I had several talks with Pfizer's scientists lately in conferences, and they pretty much re-affirmed the same idea. I think stock buy-back, dividend increase or increased R&D will make me happy. da bull

To: YORE who wrote (4929)	8/14/1998 8:43:00 AM
From: BigKNY3	Read Replies (2) \| Respond to of 9523

YORE; <<One thing that escapes me on this thread(I think it is a great thread with lots of good unbiased information and in most cases sound analysis.)is that no one is adressing the impact of PFE selling the medical equipment business and what they intend to do with the billions of dollars they expect to receive.>> YORE: At this point, I don't think anyone knows.... including PFE management. It was more a PFE strategy to remove low margin medical products from their portfolio and concentrate on pharmaceuticals. Along with MRK, PFE is now the purest pharmaceutical play in the industry. The funds from these sales will probably be used to fund expanded R&D, the expansion of the field force, more licensing agreements, and any other product or company opportunities that may appear. Have PFun! BigKNY3